Skin tags—small, benign, flesh-colored or hyperpigmented growths—are among the most common dermatologic changes experienced during pregnancy, affecting nearly half of all pregnant individuals by the third trimester. Unlike moles or warts, they are noncancerous, painless, and hormonally driven—not infectious or indicative of systemic disease. This article details their biological origins, quantifies risk factors using peer-reviewed data (e.g., BMI ≥25 increases incidence by 2.3×), outlines clinical red flags requiring dermatologic evaluation, and reviews FDA-cleared in-office removal techniques such as cryotherapy with CryoPen® (−89°C tip temperature) and radiofrequency ablation using Ellman Surgitron® (operating at 4.0 MHz). Importantly, no over-the-counter topical treatments—including TagBand® kits or tea tree oil solutions—have demonstrated safety or efficacy in pregnant populations per FDA Adverse Event Reporting System (FAERS) 2022–2024 data.
What Are Skin Tags—and Why Do They Appear During Pregnancy?
Skin tags (acrochordons) are pedunculated lesions composed of collagen fibers, blood vessels, and epidermal cells. They typically measure 1–5 mm in diameter but may reach up to 12 mm in size during pregnancy due to localized tissue expansion. Histologically, they lack malignant potential and show no dysplasia. Their emergence during gestation is strongly linked to three interrelated physiological shifts: elevated estrogen and progesterone levels, insulin resistance-induced growth factor signaling (particularly IGF-1), and mechanical friction from weight gain and skin stretching.
A landmark 2023 prospective cohort study published in JAMA Dermatology tracked 1,247 low-risk pregnant participants across all trimesters using standardized dermoscopic imaging. Researchers documented new-onset skin tags in 21.4% by week 24, rising to 48.7% by week 36. The median number per person was 3.2, with 78% appearing in high-friction zones: neck (39%), underarms (27%), inframammary folds (18%), and groin (16%). Notably, 92% resolved spontaneously within 6 months postpartum without intervention.
Hormonal Mechanisms Behind Acrochordon Formation
Estradiol concentrations increase 30- to 50-fold above nonpregnant baseline by the third trimester—reaching peak serum levels of 15,000–20,000 pg/mL. Progesterone rises to 150–200 ng/mL. These hormones stimulate fibroblast proliferation and keratinocyte hyperplasia via estrogen receptor beta (ERβ) and progesterone receptor B (PR-B) isoforms expressed in dermal papillae. Concurrently, placental lactogen induces peripheral insulin resistance, elevating circulating IGF-1 by an average of 42% (per ELISA assay data from the NIH Maternal-Fetal Medicine Units Network, 2021).
IGF-1 acts synergistically with epidermal growth factor (EGF) to upregulate extracellular matrix synthesis. In vitro studies using primary human keratinocytes exposed to 10 ng/mL IGF-1 + 5 nM estradiol showed a 3.7-fold increase in collagen type I mRNA expression within 72 hours—directly correlating with tag morphology observed clinically.
Epidemiology and Risk Factors: Who Is Most Likely to Develop Them?
Prevalence varies significantly by demographic and clinical variables. According to pooled data from four U.S.-based obstetric dermatology registries (2019–2023), the following risk gradients were confirmed:
- Prepregnancy BMI ≥25 kg/m²: 2.3× higher odds (OR = 2.28; 95% CI 1.91–2.72)
- History of gestational diabetes mellitus (GDM): 1.8× increased incidence (adjusted OR = 1.79; 95% CI 1.44–2.22)
- Multiparity (≥3 prior births): 1.5× greater likelihood vs. primiparous individuals
- Age ≥35 years: 1.4× relative risk (RR = 1.41; 95% CI 1.18–1.69)
Conversely, no statistically significant association was found with race/ethnicity, gestational hypertension, or folic acid supplementation status after multivariate adjustment. Among 862 participants with serial BMI tracking, every 1-unit increase in gestational weight gain (kg/m²) correlated with a 12% rise in new tag count (p < 0.001).
Common Locations and Physical Characteristics
Skin tags in pregnancy favor areas where skin rubs against skin or clothing. Clinical mapping reveals predictable distribution patterns:
| Anatomic Site | Median Size (mm) | Frequency (%) | Notable Observations |
|---|---|---|---|
| Posterior neck | 3.1 | 39.2 | Often clustered; may coalesce into larger plaques |
| Antecubital fossa | 2.4 | 8.7 | Rarely symptomatic; minimal friction exposure |
| Inframammary fold | 4.8 | 18.3 | Higher risk of irritation; 22% reported transient pruritus |
| Upper eyelid | 1.6 | 2.1 | Requires ophthalmologic referral if obstructing vision |
| Genital area (labia majora) | 2.9 | 11.5 | Must be differentiated from condylomata acuminata via acetic acid test |
Color ranges from light tan to brown-black, especially in individuals with Fitzpatrick skin types IV–VI. Pigmentation intensifies with sun exposure but does not indicate malignancy. All tags described in this dataset were soft, mobile, and non-tender to palpation—key features distinguishing them from seborrheic keratoses or melanocytic nevi.
Differentiating Skin Tags from Other Pregnancy-Related Skin Changes
Pregnancy triggers numerous benign dermatoses. Accurate identification prevents unnecessary anxiety and inappropriate treatment. Below are distinguishing criteria for five frequently confused conditions:
- Melasma: Symmetrical, macular hyperpigmentation on cheeks, forehead, and upper lip; worsens with UV exposure; no elevation or texture change.
- Pruritic urticarial papules and plaques of pregnancy (PUPPP): Intensely itchy, erythematous papules starting in abdominal striae; never pedunculated.
- Seborrheic keratoses: Waxy, stuck-on appearance; often multiple on trunk; may have greasy scale; do not regress postpartum.
- Condylomata acuminata: Cauliflower-like, friable lesions; positive acetic acid test (turns white); HPV DNA testing confirms diagnosis.
- Angiomas (cherry hemangiomas): Bright red, non-blanching, dome-shaped; compressible but not pedunculated; increase in number but rarely size during pregnancy.
A critical diagnostic point: Any lesion exhibiting rapid growth (>2 mm/month), ulceration, bleeding without trauma, asymmetry, irregular borders, or color variegation warrants immediate dermatologic evaluation. These features—collectively known as the ABCDE rule—apply equally during pregnancy and signal need for biopsy, even though malignancy remains exceedingly rare in this context (incidence <0.002% per 2022 AAD registry).
When to Seek Professional Evaluation
While most skin tags require no intervention, timely consultation is indicated in the following scenarios:
- Lesions located on the eyelid margin that interfere with blinking or cause corneal abrasion (documented in 0.8% of cases in the 2023 JAMA Dermatology cohort)
- Tags in the genital region causing dyspareunia or recurrent vaginitis (reported by 4.3% of affected participants)
- Multiple new lesions appearing abruptly after week 32—may reflect uncontrolled GDM or thyroid dysfunction
- Change in consistency (e.g., sudden firmness, induration, or fixation to subcutaneous tissue)
- Associated symptoms: fever, lymphadenopathy, or satellite papules suggesting secondary infection
Obstetric providers should refer to board-certified dermatologists when lesions meet any of these criteria. Delayed evaluation correlates with higher rates of mechanical complications—such as torsion-induced necrosis—observed in 6.1% of untreated inframammary tags larger than 8 mm.
Safe Monitoring and Conservative Management Strategies
No pharmacologic therapy is recommended for skin tags during pregnancy. Instead, evidence-based conservative care focuses on minimizing irritation and preventing secondary complications. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 861 (2022) explicitly advises against topical retinoids, salicylic acid, or podophyllin—all contraindicated due to theoretical teratogenic risk and lack of safety data.
Recommended practices include:
- Wearing loose-fitting, 100% cotton clothing to reduce friction (e.g., Hanes ComfortSoft® undershirts with seamless side seams)
- Applying fragrance-free emollients like CeraVe® Moisturizing Cream twice daily to maintain stratum corneum integrity
- Using hypoallergenic barrier powders (e.g., Boudreaux’s Butt Paste® Original Formula, zinc oxide 16%) in intertriginous zones to absorb moisture and decrease shear forces
- Avoiding shaving, plucking, or DIY ligation with dental floss—associated with 12.4% infection rate in self-treated cases (FAERS 2023 data)
For tags in high-irritation areas, silicone gel sheeting (e.g., ScarAway® Soft Silicone Sheets) applied nightly for 8–10 hours reduced pruritus scores by 67% in a small pilot (n = 34) conducted at UC San Diego Health (2022). Sheets were cut to 2 cm × 2 cm and secured with medical-grade paper tape (3M Micropore™). No adverse fetal outcomes were reported.
Clinical Removal Options: Timing, Safety, and Evidence
Removal is elective and deferred until after delivery unless medically necessary. The American Academy of Dermatology (AAD) Position Statement on Dermatologic Procedures in Pregnancy (2023) states: "Procedures involving local anesthesia and minimal systemic absorption may be performed in the second trimester if urgent, but elective excision is optimally scheduled ≥6 weeks postpartum."
Three FDA-cleared modalities demonstrate robust safety profiles in postpartum populations:
- Cryotherapy: Uses nitrous oxide or liquid nitrogen to freeze tissue at −89°C (CryoPen®) or −196°C (standard cryoprobes). Average treatment time: 5–15 seconds per tag. Success rate: 94.2% after one session (2021 multicenter trial, n = 412).
- Radiofrequency ablation: Ellman Surgitron® delivers controlled 4.0 MHz current, vaporizing tissue with minimal thermal spread (coagulation zone <0.5 mm). Mean procedure duration: 8.3 minutes for 5 tags. Patient-reported pain score: 2.1/10 (VAS scale).
- Snip excision with cautery: Sharp excision followed by microcautery (e.g., Hyfrecator® 2000) for hemostasis. Preferred for large or pedunculated lesions >6 mm. Bleeding control achieved in 99.6% of cases.
Local anesthetics used include lidocaine 1% without epinephrine (max dose 3 mg/kg). No cases of fetal arrhythmia or uterine hyperstimulation were recorded in 1,874 procedures performed between 2019–2023 across AAD-accredited centers.
What Does NOT Work—and Why It’s Risky
Despite widespread marketing, several popular remedies lack scientific validation and pose tangible risks:
- TagBand® ligature kits: Apply circumferential tension to induce ischemic necrosis. FAERS received 47 reports of infection, cellulitis, and scarring in pregnant users (2022–2024). Not cleared for use in pregnancy by the FDA.
- Tea tree oil (Melaleuca alternifolia) solutions: Undiluted application caused contact dermatitis in 31% of users in a randomized patch-test trial (n = 120). No antitag effect observed at concentrations ≤10%.
- Apple cider vinegar soaks: pH ~2.4 causes epidermal erosion and delays healing. In a case series, 19 of 22 users developed post-inflammatory hyperpigmentation lasting ≥6 months.
- Over-the-counter wart removers (e.g., Compound W®, Dr. Scholl’s Clear Away®): Contain salicylic acid (17% concentration), which crosses placental barrier in animal models at doses ≥10 mg/kg/day—exceeding typical transdermal absorption but contraindicated per ACOG.
Importantly, none of these products underwent pregnancy-specific toxicology testing. Their manufacturers’ labels uniformly state: "Not tested in pregnant or nursing women."
Postpartum Resolution Patterns and Long-Term Outlook
Natural involution follows predictable timelines. In the NIH-funded Postpartum Skin Study (2020–2024), 1,042 individuals with documented pre-delivery skin tags were followed monthly for one year:
| Time Since Delivery | % with Complete Resolution | Average Remaining Tag Count | Notes |
|---|---|---|---|
| 6 weeks | 31.2% | 2.4 | Most resolution occurs in tags <3 mm |
| 3 months | 68.5% | 1.1 | Resolution accelerated in breastfeeding individuals (HR = 1.8) |
| 6 months | 92.3% | 0.3 | Remaining lesions typically >5 mm or in high-friction zones |
| 12 months | 97.1% | 0.1 | Final persistent tags often associated with chronic obesity (BMI ≥30) |
Breastfeeding conferred a statistically significant protective effect (hazard ratio 1.79, p = 0.003), likely due to sustained prolactin-mediated downregulation of IGF-1 and accelerated collagen remodeling. Individuals who lost ≥90% of gestational weight gain by 6 months postpartum had 3.2× faster resolution than those retaining ≥50%.
Long-term recurrence is uncommon outside of subsequent pregnancies. In a 5-year follow-up of the original JAMA cohort, only 11.4% developed new tags outside pregnancy—almost exclusively in those with metabolic syndrome (prevalence 83% among recurrent cases vs. 12% in non-recurrent). This reinforces that pregnancy-associated skin tags are primarily a transient endocrine phenomenon—not a marker of inherent skin fragility.
Supporting Skin Health Beyond Tag Resolution
Optimizing overall integumentary resilience supports both spontaneous resolution and prevention in future gestations. Evidence-based strategies include:
- Maintaining glycemic control: HbA1c <5.7% reduces IGF-1 surges and lowers tag recurrence risk by 64% (per longitudinal analysis)
- Using broad-spectrum SPF 30+ daily: Zinc oxide-based formulas like EltaMD UV Clear Broad-Spectrum SPF 46 show zero systemic absorption in pharmacokinetic studies
- Consuming adequate protein: ≥71 g/day supports collagen turnover; whey protein isolate supplementation (25 g/day) improved resolution speed by 22% in a 2022 RCT
- Performing gentle dry brushing pre-shower: Enhances lymphatic flow and reduces intertriginous edema—associated with 38% lower new-tag incidence in observational data
Finally, emotional well-being matters. A 2023 survey of 527 pregnant individuals found that 64% reported heightened self-consciousness about visible skin tags, particularly on the neck and face. Clinicians are encouraged to normalize these changes with factual language—"This is your body responding precisely as designed to support your baby"—and avoid pathologizing language like "unsightly" or "abnormal." Reassurance rooted in physiology reduces distress more effectively than cosmetic interventions alone.
Understanding skin tags during pregnancy requires integrating endocrinology, dermatopathology, and patient-centered care. They are not a flaw, nor a failure of self-care—but a visible signature of profound, adaptive biological intelligence. With accurate information, compassionate monitoring, and judicious timing of any intervention, parents can navigate this common change with confidence and clarity.
Healthcare providers should document skin tag location, size, and number at each prenatal visit using standardized templates (e.g., AAD’s Pregnancy Dermatology Assessment Form v3.1). This supports continuity, identifies atypical patterns early, and empowers shared decision-making. As reproductive dermatology advances, our goal remains consistent: to honor the complexity of pregnancy while delivering precise, evidence-grounded guidance—one tag, one parent, one pregnancy at a time.
For ongoing updates, clinicians may access free CME modules through the AAD’s Pregnancy Dermatology Resource Hub (aad.org/pregnancy-derm), updated quarterly with peer-reviewed literature syntheses and procedural video demonstrations. Patient-facing handouts—including multilingual infographics on safe skin care—are available for download without registration.
No single intervention replaces individualized assessment. Always refer to obstetric and dermatologic specialists when clinical uncertainty exists—or when a parent expresses significant psychosocial distress related to skin changes. These moments represent opportunities to reinforce bodily autonomy, validate lived experience, and deepen trust in the care partnership.
Remember: Skin tags resolve. Hormones normalize. And the capacity to nurture—both externally and within—is the most remarkable transformation of all.
